View Exam | PowerPak

1. Which term describes the phenomenon of patients experiencing a vascular event after being aggressively treated for cardiovascular disease risk factor reduction with current evidence-based recommendations?

A. Cardiovascular outcome trial B. BARI-2 effect C. Residual risk D. None of the above

2. Which of the following diabetes medications have reported reductions in cardiovascular disease outcomes from cardiovascular outcome trials in type 2 diabetes mellitus?

A. Empagliflozin and liraglutide B. Sitagliptin and empagliflozin C. Insulin glargine and sitagliptin D. Insulin degludec and saxagliptin

3. What effect do dipeptidyl peptidase-4 inhibitors have on the risks of death, myocardial infarction, and stroke according to cardiovascular outcome trials conducted to date?

A. A negative effect B. A neutral effect C. A positive effect D. A varied effect

4. Empagliflozin decreased which of the following outcomes?

A. All-cause mortality B. Myocardial infarction C. Stroke D. Amputations

5. Real world, retrospective data demonstrated that death and heart failure were reduced with the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Which SGLT-2 inhibitors were most common among participants?

A. Saxagliptin and sitaglitptin B. Empagliflozin and dapagliflozin C. Dapagliflozin and canagliflozin D. Saxagliptin and canagliflozin

6. Which of the following outcomes dictates that pioglitazone will likely not be used for first-line prevention of cardiovascular disease?

A. Weight gain B. Bone fracture risk in older adults C. Development of heart failure D. All of the above

7. A patient has had a myocardial infarction. Which glucagon-like peptide-1 receptor agonist has been shown to decrease the risk of a recurrent MI?

A. Lixisenatide B. Liraglutide C. Exenatide D. All of the above

8. A patient with type 2 diabetes mellitus is committed to lifestyle changes to manage his disease, and he currently takes a sulfonylurea and metformin at maximum tolerated doses. His hemoglobin A1c level is 9%. He also takes a statin and 2 blood pressure medications, including lisinopril 80 mg daily; he has microalbuminuria and an estimated glomerular filtration rate of 78 ml/min/1.73 m2. Which medication could be added to this patient's regimen to help with glycemic control and slow progression of renal disease?

A. Empagliflozin B. Sitagliptin C. Lixisenatide D. Insulin glargine

9. The Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) reported what cardiovascular results with long-acting insulins?

A. Insulin degludec was superior to insulin glargine for reducing strokes B. Insulin degludec was associated with more hypoglycemia than insulin glargine C. Insulin degludec was inferior to insulin glargine for reducing strokes D. Insulin degludec was non-inferior to insulin glargine for cardiovascular disease outcomes

10. The mechanisms for cardiovascular disease improvement with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists are likely the same.

A. True B. False

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which term describes the phenomenon of patients experiencing a vascular event after being aggressively treated for cardiovascular disease risk factor reduction with current evidence-based recommendations?

2. Which of the following diabetes medications have reported reductions in cardiovascular disease outcomes from cardiovascular outcome trials in type 2 diabetes mellitus?

3. What effect do dipeptidyl peptidase-4 inhibitors have on the risks of death, myocardial infarction, and stroke according to cardiovascular outcome trials conducted to date?

4. Empagliflozin decreased which of the following outcomes?

5. Real world, retrospective data demonstrated that death and heart failure were reduced with the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Which SGLT-2 inhibitors were most common among participants?

6. Which of the following outcomes dictates that pioglitazone will likely not be used for first-line prevention of cardiovascular disease?

7. A patient has had a myocardial infarction. Which glucagon-like peptide-1 receptor agonist has been shown to decrease the risk of a recurrent MI?

9. The Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) reported what cardiovascular results with long-acting insulins?

10. The mechanisms for cardiovascular disease improvement with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists are likely the same.

« Return to Activity

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which term describes the phenomenon of patients experiencing a vascular event after being aggressively treated for cardiovascular disease risk factor reduction with current evidence-based recommendations?

2. Which of the following diabetes medications have reported reductions in cardiovascular disease outcomes from cardiovascular outcome trials in type 2 diabetes mellitus?

3. What effect do dipeptidyl peptidase-4 inhibitors have on the risks of death, myocardial infarction, and stroke according to cardiovascular outcome trials conducted to date?

4. Empagliflozin decreased which of the following outcomes?

5. Real world, retrospective data demonstrated that death and heart failure were reduced with the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Which SGLT-2 inhibitors were most common among participants?

6. Which of the following outcomes dictates that pioglitazone will likely not be used for first-line prevention of cardiovascular disease?

7. A patient has had a myocardial infarction. Which glucagon-like peptide-1 receptor agonist has been shown to decrease the risk of a recurrent MI?

9. The Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) reported what cardiovascular results with long-acting insulins?

10. The mechanisms for cardiovascular disease improvement with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists are likely the same.

« Return to Activity

Customers who Purchased
this Activity also Purchased